NVS - Novartis AG
| Previous Close | 77.88 |
| Open | 77.86 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 77.51 - 77.95 |
| 52 Week Range | 75.62 - 94.19 |
| Volume | 1,180,753 |
| Avg. Volume | 1,894,969 |
| Market Cap | 181.797B |
| Beta | 0.88 |
| PE Ratio (TTM) | 23.88 |
| EPS (TTM) | 3.25 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.98 (3.67%) |
| Ex-Dividend Date | 2018-03-06 |
| 1y Target Est | 98.06 |
Yahoo Finance Video•6 days agoNYSE trader: Watch for earnings from these key stocks
Matthew Cheslock joins Yahoo Finance's Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.
- Zacks•4 days ago
Shire (SHPG) Turns Down Takeda's Third Buyout Proposition
Shire (SHPG) declines Takeda Pharmaceutical's third acquisition offer in a cash-stock deal.
- Zacks•4 days ago
What's in the Cards for Glaxo (GSK) This Earnings Season?
Strong sales in Glaxo's (GSK) Pharmaceuticals and Vaccines business segment might aid the company's results in Q1.
- Zacks•4 days ago
Novartis (NVS) Reports Encouraging Data on MS Candidate
Novartis (NVS) announces encouraging results from a phase III study, EXPAND, on siponimod (BAF312) in patients with secondary progressive multiple sclerosis.
- Zacks•4 days ago
Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR
Novartis (NVS) and J&J (JNJ) deliver strong Q1 results. Merck (MRK) and Bristol Myers (BMY) present lung cancer data at AACR.
- Zacks•4 days ago
J&J, Novartis' Q1 Earnings Impress: Will Others Follow Suit?
Johnson & Johnson (JNJ) and Novartis reported strong first-quarter 2018 earnings results earlier this week.
- Investor's Business Daily•4 days ago
Novartis Stock Dips After Cosentyx Sales, Sandoz Generics Disappoint
Novartis beat earnings and revenue forecasts, but generics revenue tumbled and a key drug missed sales estimates.
- InvestorPlace•5 days ago
Novartis AG (ADR) Stock Drops on Q1 Earnings Miss
Novartis AG (ADR) (NYSE:NVS) stock took a hit on Thursday following the release of its earnings report for the first quarter of 2018.Source: Shutterstock
Motley Fool•5 days agoNovartis AG (NVS) Q1 2018 Earnings Conference Call Transcript
NVS earnings call for the period ending March 31, 2018.
- Zacks•5 days ago
Novartis (NVS) Beats Earnings and Revenue Estimates in Q1
Novartis reported encouraging results for the first quarter as sales and earnings both topped expectations on Cosentyx and Entresto strength.
- PR Newswire•5 days ago
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of AveXis, Inc. - AVXS
NEW YORK , April 19, 2018 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
- Zacks•5 days ago
Sanofi to Divest European Generic Unit, Streamline Business
Sanofi (SNY) announces sale of its European generic unit, Zentiva, for $2.4 billion.
Reuters•5 days agoNovartis CEO feels heat on U.S. generics, Cosentyx drop
Swiss drugmaker Novartis' (NOVN.S) first quarterly results under new CEO Vas Narasimhan have been marred by a prized psoriasis treatment that disappointed and a sharp slump in sales by its U.S. generics unit. While Narasimhan confirmed 2018 growth targets, his Cosentyx drug for psoriasis and arthritis missed analyst expectations with revenue plunging from the fourth quarter.
- Reuters•5 days ago
Novartis CEO feels heat on U.S. generics, Cosentyx drop
Swiss drugmaker Novartis' first quarterly results under new CEO Vas Narasimhan have been marred by a prized psoriasis treatment that disappointed and a sharp slump in sales by its U.S. generics unit. While Narasimhan confirmed 2018 growth targets, his Cosentyx drug for psoriasis and arthritis missed analyst expectations with revenue plunging from the fourth quarter.
Market Realist•5 days agoVyxeos Could Be Jazz Pharmaceuticals’ Long-Term Growth Driver
In 4Q17, Jazz Pharmaceuticals’ (JAZZ) Vyxeos (daunorubicin and cytarabine) generated revenues of $24 million compared to $10 million in 3Q17. In fiscal 2017, Vyxeos reported net revenues of $34 million.
- Associated Press•5 days ago
Novartis: 1Q Earnings Snapshot
On a per-share basis, the Basel, Switzerland-based company said it had net income of 86 cents. Earnings, adjusted for non-recurring costs, came to $1.28 per share. The drugmaker posted revenue of $12.69 ...
- Financial Times•5 days ago
[$$] Cancer and heart drugs boost Novartis sales
Swiss drugmaker Novartis reported a 22 per cent rise in net income to $2.03bn on Thursday, thanks in large part to increased sales of its cancer and heart drugs portfolio. The company confirmed its growth ...
- Associated Press•5 days ago
Novartis 1Q profit jumps 12 percent as heart drug sales soar
GENEVA (AP) — Swiss pharmaceuticals company Novartis says net income jumped 12 percent in the first quarter, pointing to explosive growth in its heart-failure drug Entresto as its rollout continues, and powerful double-digit percentage growth for psoriasis drug Cosentyx.
- The Wall Street Journal•5 days ago
[$$] Novartis Buoyed by Heart Drug
Swiss pharma giant Novartis said its first-quarter net profit rose to $2.03 billion, boosted by drugs Entresto and Cosentyx.
- Financial Times•5 days ago
[$$] Greek parliament ends probe into bribery allegations
Greece's parliament has ended a probe into allegations that 10 senior politicians, including two former prime ministers, the governor of the central bank and the country's current EU commissioner, accepted ...
- Zacks•5 days ago
Roche Hemophilia Drug Gets Breakthrough Therapy Designation
The FDA grants Breakthrough Therapy Designation to Roche's (RHHBY) Hemlibra for treatment of people with hemophilia A without factor VIII inhibitors.
- Market Realist•5 days ago
Jazz Pharmaceuticals’ Xyrem, Erwinase, and Defitelio
In 4Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of $312.5 million compared to $291 million in 4Q16. In fiscal 2017, Xyrem reported revenues of $1.2 billion compared to $1.1 billion in 2016, which reflected a 7% growth on a YoY basis. Xyrem is used for the treatment of cataplexy in narcolepsy and excessive daytime sleepiness in narcolepsy.
Market Realist•5 days agoHow Exelixis’s Cabomeytx and Cometriq Performed in 4Q17 and 2017
In 4Q17, Exelixis’s (EXEL) Cabometyx reported revenue of $90.4 million compared to $44.7 million in 4Q16, which reflected a ~102% rise on a YoY (year-over-year) basis. The FDA’s approval of the drug’s label expansion also boosted its revenue growth in 4Q17. In 2017, Cabometyx generated revenue of $324 million compared to $93.5 million in 2016.
- Market Realist•6 days ago
Analysts’ Recommendations for Novartis on April 17
Novartis AG (NVS) reported revenue of $12.9 billion and EPS (earnings per share) of $1.21 in 4Q17, a 4.8% rise in revenue compared to 4Q16. For 1Q18, analysts expect Novartis to see EPS of $1.28 on revenue of $12.6 billion.
- Zacks•6 days ago
Amgen's Aimovig Reduces Episodic Migraine in 30% Patients
Amgen (AMGN) releases full data from the phase IIIb trial, evaluating the efficacy and safety of Aimovig on patients suffering episodic migraine with multiple treatment failures.
